vs
HAIN CELESTIAL GROUP INC（HAIN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
HAIN CELESTIAL GROUP INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.9倍（$384.1M vs $207.3M），HAIN CELESTIAL GROUP INC净利率更高（-30.2% vs -62.0%，领先31.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -6.7%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -6.4%）
海恩 celestial集团是一家总部设在美国的国际食品与个人护理企业，主打天然食品与有机个人护理产品。公司1993年以海恩食品集团的名称成立，2000年与Celestial Seasonings合并后改用现名，在纳斯达克挂牌上市，旗下拥有艾拉厨房、Frank Cooper's、琳达麦卡特尼食品等多个品牌。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
HAIN vs RARE — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $384.1M | $207.3M |
| 净利润 | $-116.0M | $-128.6M |
| 毛利率 | 19.4% | — |
| 营业利润率 | -25.7% | -54.7% |
| 净利率 | -30.2% | -62.0% |
| 营收同比 | -6.7% | 25.9% |
| 净利润同比 | -11.6% | 3.5% |
| 每股收益（稀释后） | $-1.28 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $384.1M | $207.3M | ||
| Q3 25 | $367.9M | $159.9M | ||
| Q2 25 | $363.3M | $166.5M | ||
| Q1 25 | $390.4M | $139.3M | ||
| Q4 24 | $411.5M | $164.6M | ||
| Q3 24 | $394.6M | $139.5M | ||
| Q2 24 | $418.8M | $147.0M | ||
| Q1 24 | $438.4M | $108.8M |
| Q4 25 | $-116.0M | $-128.6M | ||
| Q3 25 | $-20.6M | $-180.4M | ||
| Q2 25 | $-272.6M | $-115.0M | ||
| Q1 25 | $-134.6M | $-151.1M | ||
| Q4 24 | $-104.0M | $-133.2M | ||
| Q3 24 | $-19.7M | $-133.5M | ||
| Q2 24 | $-2.9M | $-131.6M | ||
| Q1 24 | $-48.2M | $-170.7M |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 18.5% | — | ||
| Q2 25 | 20.5% | — | ||
| Q1 25 | 21.7% | — | ||
| Q4 24 | 22.7% | — | ||
| Q3 24 | 20.7% | — | ||
| Q2 24 | 23.4% | — | ||
| Q1 24 | 22.1% | — |
| Q4 25 | -25.7% | -54.7% | ||
| Q3 25 | -1.9% | -106.9% | ||
| Q2 25 | -69.3% | -64.8% | ||
| Q1 25 | -31.0% | -102.6% | ||
| Q4 24 | -22.3% | -74.3% | ||
| Q3 24 | 0.8% | -94.6% | ||
| Q2 24 | 2.9% | -79.1% | ||
| Q1 24 | -6.4% | -151.9% |
| Q4 25 | -30.2% | -62.0% | ||
| Q3 25 | -5.6% | -112.8% | ||
| Q2 25 | -75.0% | -69.0% | ||
| Q1 25 | -34.5% | -108.5% | ||
| Q4 24 | -25.3% | -80.9% | ||
| Q3 24 | -5.0% | -95.7% | ||
| Q2 24 | -0.7% | -89.5% | ||
| Q1 24 | -11.0% | -156.8% |
| Q4 25 | $-1.28 | $-1.28 | ||
| Q3 25 | $-0.23 | $-1.81 | ||
| Q2 25 | $-3.03 | $-1.17 | ||
| Q1 25 | $-1.49 | $-1.57 | ||
| Q4 24 | $-1.15 | $-1.34 | ||
| Q3 24 | $-0.22 | $-1.40 | ||
| Q2 24 | $-0.03 | $-1.52 | ||
| Q1 24 | $-0.54 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.0M | $421.0M |
| 总债务越低越好 | $388.0K | — |
| 股东权益账面价值 | $330.2M | $-80.0M |
| 总资产 | $1.5B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
| Q4 25 | $68.0M | $421.0M | ||
| Q3 25 | $47.9M | $202.5M | ||
| Q2 25 | $54.4M | $176.3M | ||
| Q1 25 | $44.4M | $127.1M | ||
| Q4 24 | $56.2M | $174.0M | ||
| Q3 24 | $56.9M | $150.6M | ||
| Q2 24 | $54.3M | $480.7M | ||
| Q1 24 | $49.5M | $112.3M |
| Q4 25 | $388.0K | — | ||
| Q3 25 | $708.6M | — | ||
| Q2 25 | $697.2M | — | ||
| Q1 25 | $701.4M | — | ||
| Q4 24 | $721.1M | — | ||
| Q3 24 | $732.8M | — | ||
| Q2 24 | $736.5M | — | ||
| Q1 24 | $769.9M | — |
| Q4 25 | $330.2M | $-80.0M | ||
| Q3 25 | $445.0M | $9.2M | ||
| Q2 25 | $475.0M | $151.3M | ||
| Q1 25 | $696.7M | $144.2M | ||
| Q4 24 | $804.7M | $255.0M | ||
| Q3 24 | $963.7M | $346.8M | ||
| Q2 24 | $942.9M | $432.4M | ||
| Q1 24 | $944.5M | $140.3M |
| Q4 25 | $1.5B | $1.5B | ||
| Q3 25 | $1.6B | $1.2B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $2.0B | $1.5B | ||
| Q3 24 | $2.1B | $1.5B | ||
| Q2 24 | $2.1B | $1.6B | ||
| Q1 24 | $2.1B | $1.3B |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 1.59× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.01× | — | ||
| Q4 24 | 0.90× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $37.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $37.0M | $-99.8M | ||
| Q3 25 | $-8.5M | $-91.4M | ||
| Q2 25 | $-2.6M | $-108.3M | ||
| Q1 25 | $4.6M | $-166.5M | ||
| Q4 24 | $30.9M | $-79.3M | ||
| Q3 24 | $-10.8M | $-67.0M | ||
| Q2 24 | $39.4M | $-77.0M | ||
| Q1 24 | $42.3M | $-190.7M |
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAIN
| Other | $175.5M | 46% |
| Snacks | $71.9M | 19% |
| Baby Kids | $53.6M | 14% |
| Western Europe | $50.5M | 13% |
| CA | $20.9M | 5% |
| Personal Care | $11.9M | 3% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
